Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | ADA | P00813 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1378135 | 1.00 | KDM4E (0.60) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL38653234 | 0.88 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL12149981 | 0.88 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL20977435 | 0.86 | KDM4E (0.43) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL7251830 | 0.84 | KDM4E (0.56) | KDM4ETAS1R3TAS1R1HPGDPOLA1 | |
| SCHEMBL1374928 | 0.84 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL1374924 | 0.84 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL12758450 | 0.83 | HPGD (0.46) | KDM4EHPGDPOLA1ADORA2AADORA3 | |
| SCHEMBL17357693 | 0.83 | HPGD (0.46) | KDM4EHPGDPOLA1ADORA2AADORA3 | |
| SCHEMBL29138074 | 0.83 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1HPGDPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120566-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | disclosed |
| US-7902202-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2120566-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090238790-A2 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2008082601-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238790-A2 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GYS2 | KDM4E 4502/4885TAS1R3 4760/4885TAS1R1 4791/4885 |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | KDM4E 4502/4885TAS1R3 4760/4885TAS1R1 4791/4885 |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | KDM4E 4502/4885TAS1R3 4760/4885TAS1R1 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.